Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 9/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30469481 | 0.80 | GRM5 (0.69) | GRM5FFAR1ACHECA12CA1 | |
| SCHEMBL30469478 | 0.80 | GRM5 (0.69) | GRM5FFAR1ACHECA12CA1 | |
| SCHEMBL4562089 | 0.80 | GRM5 (0.69) | GRM5FFAR1ACHECA12CA1 | |
| SCHEMBL3154822 | 0.77 | GRM5 (0.47) | GRM5CYP1A2CYP3A4FFAR1ACHE | |
| SCHEMBL14418971 | 0.77 | FFAR1 (0.49) | GRM5CYP1A2CYP3A4FFAR1FFAR4 | |
| SCHEMBL7132620 | 0.76 | GRM5 (0.59) | GRM5FFAR1ACHECA12CA1 | |
| SCHEMBL96225 | 0.76 | — | — | |
| SCHEMBL19128668 | 0.76 | ALDH1A1 (0.45) | GRM5CA1CA2CA9SMN1; SMN2 | |
| SCHEMBL1431909 | 0.76 | CA12 (0.50) | GRM5CYP3A4CA12CA1CA2 | |
| SCHEMBL136231 | 0.76 | KCNH2 (0.49) | GRM5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590985-B1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2014-05-14 | — | — | EP | disclosed |
| US-8580962-B2 | Spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD. (IT) | 2013-11-12 | — | — | US | disclosed |
| EP-2590985-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2013-05-15 | — | — | EP | disclosed |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD. (IT) | 2012-03-08 | — | — | US | disclosed |
| WO-2012004400-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-01-12 | — | — | WO | disclosed |
| EP-1753719-B1 | SUBSTITUTED PYRROLIDINE-2-ONES | NOVARTIS AG (CH) | 2010-03-03 | — | — | EP | disclosed |
| US-20070172421-A1 | Substituted pyrrolidine-2-ones | NOVARTIS AG (CH) | 2007-07-26 | — | — | US | disclosed |
| EP-1753719-A1 | SUBSTITUTED PYRROLIDINE-2-ONES | Novartis AG (CH) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118535-A1 | SUBSTITUTED PYRROLIDINE-2-ONES | NOVARTIS AG (CH) | 2005-12-15 | — | — | WO | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| EP-0395768-A1 | SUBSTITUTED ALLYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070172421-A1 | Substituted pyrrolidine-2-ones | PRLHR, EPOR, FLT1 | GRM5 2378/4885CYP1A2 217/4885CYP3A4 246/4885 |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GPR65, GRIK5 | GRM5 1/4885CYP1A2 3174/4885CYP3A4 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.